Erypeg 50mcg Injection contains Pegylated Recombinant Human Erythropoietin, a long-acting erythropoiesis-stimulating agent used to treat anemia associated with chronic kidney disease (CKD), chemotherapy, or other conditions resulting in insufficient endogenous erythropoietin production. The pegylation process extends the half-life of erythropoietin, allowing for less frequent dosing compared to non-pegylated formulations. Erypeg stimulates erythroid progenitor cells in the bone marrow, promoting red blood cell production and improving hemoglobin levels. It is indicated for the treatment of anemia in adult patients with CKD on dialysis or not on dialysis, as well as anemia due to myelosuppressive chemotherapy in non-myeloid malignancies. The injection is administered subcutaneously or intravenously under medical supervision, with dosing individualized based on patient response and hemoglobin levels. Monitoring of hemoglobin, iron status, and blood pressure is essential during therapy to avoid adverse effects such as hypertension, thromboembolic events, or pure red cell aplasia. Erypeg should be used cautiously in patients with uncontrolled hypertension or hypersensitivity to erythropoietin products. Proper patient selection and adherence to recommended dosing guidelines optimize therapeutic outcomes and minimize risks associated with erythropoiesis-stimulating agents.